After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex...
FDA Guidance titled “Further Testing of Donations that are Reactive on a Licensed Donor Screen...
As a friendly reminder, airlines often change their routine flights and cargo hours for hol...
Currently, there are limited supplies of the reagents used for HIV-1 Western Blot and HIV-2 EIA test...
Reminder - On Wednesday June 6, 2018 at 10:00AM PST, we will be hosting a webinar regarding the chan...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...